Medical devices manufacturer Coloplast (OMX: COLO B) revenues grew by 7% to 5.35 billion DKK in the first half of 2011/2012 fiscal year. Gross margin of 66% and EBIT margin of 27% meant that the bottom line looks nice as well. Q2 revenues were about 2.7 billion with profit for the period at 514 million.
Business areas Ostomy, Continence and Urology Care reported high single digit revenue growth where as Wound & Skin Care sales fell by one percent. The firm still expects organic revenue growth of 6% and raises EBIT margin guidance from 27% to 28%. In the beginning of April the share briefly touched 100o DKK. Today it reclaimed that level and closed at an all time up by nearly 6%.
No comments:
Post a Comment